May 29, 2023
Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study
May 25, 2023
Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting
May 24, 2023
Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer
Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial
May 16, 2023
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
May 15, 2023
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer
May 09, 2023
Immutep to Participate in the JMP Securities Life Sciences Conference
May 02, 2023
Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma
Apr 30, 2023
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
Apr 26, 2023
Immutep Quarterly Activities Report
Immutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meeting
Immutep Appoints Dr. Florian Vogl as Chief Medical Officer
Apr 16, 2023
Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting
Apr 11, 2023
Immutep Announces Changes to the Board
Mar 31, 2023
Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023
